ACTA VIROLOGICA, a key journal in the field of virology and infectious diseases, is published by FRONTIERS MEDIA SA in Slovakia, serving the global scientific community with groundbreaking research since its inception in 1957. This esteemed journal, identified by ISSN 0001-723X and E-ISSN 1336-2305, provides a platform for rigorous peer-reviewed articles that contribute significantly to our understanding of viral pathogens and their implications in medicine. Positioned within the Q3 category for both Infectious Diseases and Miscellaneous Medicine, and a Q4 category for Virology in 2023, ACTA VIROLOGICA offers crucial insights into the evolving landscape of virology research. With its robust accessibility options, this journal appeals to a diverse readership, including researchers, healthcare professionals, and students, fostering a collaborative environment to advance the field of virology. The editorial objective is to enhance the catalog of knowledge pertaining to viruses, promoting innovative approaches in prevention, diagnostics, and treatment. Located at AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE CH-1015, SWITZERLAND, ACTA VIROLOGICA continues to be a vital resource in the collective efforts to combat viral disease challenges.

Journal of Virology is a premier scholarly journal dedicated to advancing the field of virology, focusing on the molecular mechanisms of virus-host interactions, viral pathogenesis, and the latest therapeutic and vaccine developments. Published by the American Society for Microbiology, this esteemed journal has been a cornerstone for researchers since its inception in 1967, providing a platform for high-quality, peer-reviewed research. With a commendable impact factor indicative of its relevance and influence, the journal is categorized in the top quartile (Q1) for Virology, Microbiology, and Insect Science, reflecting its significance in these fields. Researchers can access a wealth of studies and findings that shape our understanding of viruses and their interactions with hosts, highlighting its role in both basic and applied sciences. Positioned in the United States, the Journal of Virology serves a global audience, ensuring that cutting-edge discoveries reach professionals, students, and academics alike. Join the conversation as we explore the complexities of virology and its implications for human health and disease.

Annual Review of Virology is a premier scholarly journal published by Annual Reviews, dedicated to advancing the field of virology through comprehensive and insightful reviews. Since its inception in 2014, this journal has established itself as a leading resource for researchers, professionals, and students alike, achieving an impressive Q1 ranking in the field of Virology and a Scopus rank of #10 out of 80 in its category, placing it in the 88th percentile. The journal features in-depth analyses of the latest developments in virology, encompassing various aspects such as viral pathogenesis, host interactions, and antiviral strategies, thereby catering to a diverse audience seeking the most relevant and cutting-edge information. Although it is not Open Access, Annual Review of Virology remains an indispensable tool for those engaged in virology research, transforming complex findings into accessible knowledge that shapes future investigations and practical applications in the field.

VIRUS RESEARCH is a leading journal dedicated to the field of virology, published by Elsevier, and has been a cornerstone for researchers, professionals, and students since its inception in 1984. With an impressive impact factor, the journal is highly regarded, holding a Q2 category ranking in both Cancer Research and Infectious Diseases, as well as in Virology for 2023. Based in the Netherlands, it publishes high-quality, peer-reviewed articles that explore the intricate relationships between viruses and their hosts, novel therapeutic strategies, and advancements in virus biology. Researchers will find that it ranks 49th in Medicine - Infectious Diseases and 19th in Immunology and Microbiology - Virology according to Scopus, signifying its significant contribution and relevance in the academic world. VIRUS RESEARCH facilitates a platform for sharing groundbreaking discoveries, forming a vital part of the global scientific community, making it an essential read for those involved in the study of viral pathogens and their implications in medicine and biochemistry.

Welcome to the Journal of Virus Eradication, a premier publication dedicated to advancing the field of virology and infectious disease research. Published by MEDISCRIPT LTD, this journal provides a vital platform for sharing cutting-edge research findings in key areas including epidemiology, immunology, and public health. With an impressive classification of Q2 in Epidemiology and Infectious Diseases for 2023, this journal exemplifies a commitment to high-quality scholarship and impactful research. The Journal of Virus Eradication is instrumental in disseminating knowledge that tackles viral threats, contributing to global health initiatives aimed at virus containment and eradication. Researchers, professionals, and students alike will find this journal an invaluable resource, making significant contributions to the scientific community and society at large.

VIROLOGICA SINICA, published by KEAI PUBLISHING LTD, is a leading international journal dedicated to the field of virology. With an ISSN of 1674-0769 and E-ISSN of 1995-820X, this esteemed journal showcases cutting-edge research from 2006 to 2024, focusing on critical developments in Immunology, Infectious Diseases, Molecular Medicine, and Virology. As evidenced by its respectable positioning in the Q2 quartile of relevant categories and impressive Scopus rankings—such as Rank #20/80 in Virology—VIROLOGICA SINICA serves as an essential resource for researchers, professionals, and students aiming to deepen their understanding of viral pathogens and their impact on human health. While the journal does not currently offer open access, it remains an invaluable publication for those seeking to stay at the forefront of virology research. Its address is located at 16 Donghuangchenggen North St, Beijing, China, where it continues to foster academic excellence in the rapidly evolving landscape of virology.

ANTIVIRAL RESEARCH, published by Elsevier, stands at the forefront of the study of antiviral agents and therapy, with a dedicated focus on advancing the understanding of viral infections and their mechanisms. The journal is recognized within the top tier of academic publications, belonging to the prestigious Q1 category in both Pharmacology and Virology as of 2023, ranking 12th out of 313 in Pharmacology and 11th out of 80 in Virology according to Scopus metrics, reflecting its significant impact in the field. With a long-standing history since its inception in 1959, it continues to serve as an essential platform for researchers and health professionals alike, sharing critical findings that drive innovation in antiviral therapeutics. Although it does not currently offer open access options, the journal’s rigorous peer-review process ensures that every published article meets high academic standards, providing invaluable insights for those dedicated to enhancing public health through virology research.

Journal of Clinical Virology, published by Elsevier, stands at the forefront of virology research, focusing on the clinical implications of viral diseases. With an impressive impact factor representative of its Q1 categorization in both Infectious Diseases and Virology, this journal is essential for researchers and healthcare professionals aiming to keep pace with evolving knowledge and treatments in virology. Since its inception in 1998, it has provided a vital platform for the dissemination of significant breakthroughs, now continuing through to 2024. The journal boasts competitive Scopus ranks, placing it in the 95th percentile for Infectious Diseases and the 91st percentile for Virology. Scholars can benefit from its selective Open Access options, promoting widespread access to cutting-edge research. With an ever-increasing demand for innovative solutions to viral infections, Journal of Clinical Virology remains dedicated to fostering advancements in the field, making it a key resource for anyone invested in virology and infectious disease management.

The Journal of Clinical Virology Plus, published by Elsevier, is an essential resource for researchers and professionals in the fields of virology and infectious diseases. Launched in 2021, this journal aims to bridge the gap between clinical research and application, fostering a deeper understanding of viral pathogenesis, diagnostics, and therapeutic strategies. With an ISSN of 2667-0380, this open-access journal brings cutting-edge findings to the global scientific community, facilitating the rapid dissemination of knowledge critical for advancing public health. Positioned in the Q3 category for both Infectious Diseases and Virology in 2023, its ranking reflects its growing influence and relevance in the academic landscape. The journal strives to support innovative research, collaborative studies, and comprehensive reviews that address contemporary challenges in clinical virology. As it converges through the years from 2021 to 2024, Journal of Clinical Virology Plus aims to be a central hub for vital discussions and breakthroughs in this dynamic field.

Tumour Virus Research, an esteemed journal published by Elsevier, serves as a vital resource in the fields of cancer research, infectious diseases, and virology. With an impact factor reflective of its influence and recognized as a Q2 journal in multiple categories as of 2023, it rigorously presents high-impact research dedicated to the understanding of viral pathogens in tumorigenesis. Since its transition to an Open Access model in 2021, the journal has enhanced accessibility, empowering researchers and the academic community globally to explore cutting-edge findings. The journal covers a broad scope, encompassing the intricate interactions between viruses and cancer biology, which is crucial for developing novel therapeutic strategies. With a commitment to advancing scientific knowledge, Tumour Virus Research welcomes submissions that push the boundaries of current understanding and contribute to the ongoing battle against virus-mediated cancers, making it an indispensable publication for professionals, researchers, and students in the field.